AI-PROGNOSIS Artificial intelligence-based Parkinson’s disease risk assessment and prognosis
- Coordinator
- Aristotelio Panepistimio Thessalonikis, Greece
- Runs
- 1 July 2023 to 30 June 2027
- Status
- Running
- EU funding
- €5.3m
- Total cost
- €5.5m
- Partners
- 19 organisations in 11 countries
- Type
- Research and Innovation Action
- Grant agreement
- 101080581
What the project is doing
In the project's own words, from its summary on CORDIS.
Parkinson’s disease (PD) is the most common neurodegenerative movement disorder, with a multifactorial aetiology, heterogeneous manifestation of motor and non-motor symptoms, and no cure. PD is often missed or misdiagnosed, as early symptoms are subtle and common with other diseases, allowing for considerable damage to occur before treatment. Moreover, selecting the optimal medication regimen is usually a lengthy, “trial and error” process, leading to critical, costly non-adherence.
Following a trustworthy and inclusive approach to AI development and based on multidisciplinary expertise and broad stakeholder engagement, AI-PROGNOSIS aims to advance PD diagnosis and care by: 1) developing novel, predictive AI models for personalised PD risk assessment and prognosis (in terms of time to higher disability transition and response to medication) based on multi-source patient records and databases, including in-depth health, phenotypic and genetic data, 2) implementing a system of biomarkers informing the AI models by tracking key risk/progression markers in daily living, and ultimately 3) translating the models and digital biomarkers into a validated, privacy-aware AI-driven toolkit, supporting healthcare professionals (HCPs) in disease screening, monitoring and treatment optimization via quantitative, explainable evidence, and empowering individuals with/without PD with tailored insights for informed health management.
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Aristotelio Panepistimio Thessalonikis | Thessaloniki | Greece | Coordinator |
| Ainigma Technologies | Leuven | Belgium | Participant |
| Katholieke Universiteit Leuven | Leuven | Belgium | Participant |
| Squaredev | Bruxelles / Brussel | Belgium | Participant |
| Kypriako Idryma Erevnon Gia Ti Myiki Distrofia | Agios Dometios | Cyprus | Participant |
| Abbvie Deutschland GmbH & Co Kg | Wiesbaden | Germany | Participant |
| Neurotransdata GmbH | Neuburg An Der Donau | Germany | Participant |
| Technische Universitaet Dresden | Dresden | Germany | Participant |
| Diadikasia Business Consulting Symvouloi Epicheiriseon Ae | Athina | Greece | Participant |
| Ethniko Kentro Erevnas Kai Technologikis Anaptyxis | Thermi Thessaloniki | Greece | Participant |
| Fundacion Iniciativa Para Las Neurosciencias - Foundation for Initiatives in Neuroscience | Madrid | Spain | Participant |
| Centre Hospitalier Universitaire De Toulouse | Toulouse Cedex 3 | France | Participant |
| Netcompany S.a. | Luxembourg | Luxembourg | Participant |
| Smartsol Sia | Riga | Latvia | Participant |
| Faculdade De Motricidade Humana | Cruz Quebrada Lisboa | Portugal | Participant |
| Uppsala Universitet | Uppsala | Sweden | Participant |
| King's College London | London | United Kingdom | Associatedpartner |
| Queen Mary University of London | London | United Kingdom | Associatedpartner |
| The Chancellor, Masters and Scholars of the University of Oxford | Oxford | United Kingdom | Associatedpartner |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI